Risultati della ricerca - Semiond, Dorothée

Population pharmacokinetics of cabazitaxel in patients with advanced solid tumors di Ferron, Géraldine M., Dai, Yang, Semiond, Dorothée

Testo Testo Testo

Preclinical profile of cabazitaxel di Vrignaud, Patricia, Semiond, Dorothée, Benning, Veronique, Beys, Eric, Bouchard, Hervé, Gupta, Sunil

Testo Testo Testo

Nonlinear accumulation in the brain of the new taxoid TXD258 following saturation of P-glycoprotein at the blood–brain barrier in mice and rats di Cisternino, Salvatore, Bourasset, Fanchon, Archimbaud, Yves, Sémiond, Dorothée, Sanderink, Gérard, Scherrmann, Jean-Michel

Testo Testo Testo

Phase I dose-finding study of cabazitaxel administered weekly in patients with advanced solid tumours di Fumoleau, Pierre, Trigo, Jose Manuel, Isambert, Nicolas, Sémiond, Dorothée, Gupta, Sunil, Campone, Mario

Testo Testo Testo

Drug‐Disease Interaction and Time‐Dependent Population Pharmacokinetics of Isatuximab in Relapsed/Refractory Multiple Myeloma Patients di Fau, Jean‐Baptiste, El‐Cheikh, Raouf, Brillac, Claire, Koiwai, Kimiko, Mace, Nathalie, Campana, Frank, Semiond, Dorothee, Nguyen, Laurent

Testo Testo Testo

Joint modelling and simulation of M‐protein dynamics and progression‐free survival for alternative isatuximab dosing with pomalidomide/dexamethasone di Thai, Hoai‐Thu, Gaudel, Nadia, Cerou, Marc, Ayral, Geraldine, Fau, Jean‐Baptiste, Sebastien, Bernard, van de Velde, Helgi, Semiond, Dorothée, Veyrat‐Follet, Christine

Testo Testo Testo

A phase 1b study of isatuximab plus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma di Mikhael, Joseph, Richardson, Paul, Usmani, Saad Z., Raje, Noopur, Bensinger, William, Karanes, Chatchada, Campana, Frank, Kanagavel, Dheepak, Dubin, Franck, Liu, Qianying, Semiond, Dorothée, Anderson, Kenneth

Testo Testo Testo

PK/PD modeling analysis for dosing regimen selection of isatuximab as single agent and in combination therapy in patients with multiple myeloma di Koiwai, Kimiko, El‐Cheikh, Raouf, Thai, Hoai‐Thu, Brillac, Claire, Fau, Jean‐Baptiste, Veyrat‐Follet, Christine, Risse, Marie‐Laure, van de Velde, Helgi, Semiond, Dorothée, Nguyen, Laurent

Testo Testo Testo

Exposure‐response analyses for selection/confirmation of optimal isatuximab dosing regimen in combination with pomalidomide/dexamethasone treatment in patients with multiple myelom... di Rachedi, Fatiha, Koiwai, Kimiko, Gaudel‐Dedieu, Nadia, Sebastien, Bernard, Thai, Hoai‐Thu, Brillac, Claire, Fau, Jean Baptiste, Nguyen, Laurent, van de Velde, Helgi, Veyrat‐Follet, Christine, Semiond, Dorothée

Testo Testo Testo

Isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients with renal impairment: ICARIA-MM subgroup analysis di Dimopoulos, Meletios A., Leleu, Xavier, Moreau, Philippe, Richardson, Paul G., Liberati, Anna Marina, Harrison, Simon J., Miles Prince, H., Ocio, Enrique M., Assadourian, Sylvie, Campana, Frank, Malinge, Laure, Sémiond, Dorothée, van de Velde, Helgi, Yong, Kwee

Testo Testo Testo

A phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumab di Mikhael, Joseph, Belhadj-Merzoug, Karim, Hulin, Cyrille, Vincent, Laure, Moreau, Philippe, Gasparetto, Cristina, Pour, Ludek, Spicka, Ivan, Vij, Ravi, Zonder, Jeffrey, Atanackovic, Djordje, Gabrail, Nashat, Martin, Thomas G., Perrot, Aurore, Bensfia, Samira, Weng, Qilong, Brillac, Claire, Semiond, Dorothée, Macé, Sandrine, Corzo, Kathryn P., Leleu, Xavier

Testo Testo Testo